Immunogene Therapy for Murine Melanoma Using Recombinant Adenoviral Vectors Expressing Melanoma-Associated Antigens
Open Access
- 31 March 2000
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 1 (3), 275-284
- https://doi.org/10.1006/mthe.2000.0029
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanomaGene Therapy, 1998
- Identification of Tyrosinase-related Protein 2 as a Tumor Rejection Antigen for the B16 MelanomaThe Journal of Experimental Medicine, 1997
- Characterization of Factors Involved in Modulating Persistence of Transgene Expression from Recombinant Adenovirus in the Mouse LungHuman Gene Therapy, 1997
- Development of Cancer Immunotherapies Based on Identification of the Genes Encoding Cancer Regression AntigensJNCI Journal of the National Cancer Institute, 1996
- Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines.The Journal of Experimental Medicine, 1996
- Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen.The Journal of Experimental Medicine, 1996
- Long‐term humoral and cellular immunity induced by a single immunization with replication‐defective adenovirus recombinant vectorEuropean Journal of Immunology, 1995
- Characterization of an Adenovirus Gene Transfer Vector Containing an E4 DeletionHuman Gene Therapy, 1995
- A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.The Journal of Experimental Medicine, 1994
- The pathogenesis of cancer metastasisNature, 1980